B+
Bull case
25%
Probability
Target price
$52.00
+47.7% vs current
RAPP
Rapport TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$38.00
+7.9% vs current
B-
Bear case
30%
Probability
Target price
$24.00
-31.8% vs current
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+52.2
Score
AI commentary
Sentiment is cautious rather than outright bullish: Rapport has credible primary-source support for RAP-219's Phase 3 path and a stronger cash position than many micro/mid-cap biotech peers, but the current setup is still mainly a filing-backed monitoring story with limited fresh external confirmation since the March 10, 2026 filings and a negative deterministic directional prior [#10-K-2026-03-10] [#8-K-2026-03-10].
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystQ1 2026 filing to confirm burn and runway after Phase 3 prepHigh impact
The next quarterly filing should show whether cash burn is tracking consistently with management's statement that $490.5 million of cash, cash equivalents and short-term investments at December 31, 2025 can fund operations into the second half of 2029 as RAP-219 moves toward late-stage development [#10-K-2026-03-10] [#8-K-2026-03-10].
2026-06-30eventRAP-219 Phase 3 program initiation in focal onset seizuresHigh impact
The clearest forward catalyst is execution against management's stated plan to initiate two parallel global Phase 3 trials in the second quarter of 2026 after the December 2025 end-of-Phase-2 FDA meeting supported advancement into Phase 3; a visible start would modestly de-risk the story, while any slip would likely hurt sentiment [#10-K-2026-03-10].
2026-12-31catalystSustained Phase 3 enrollment and external validation of RAP-219 platform valueHigh impact
Longer term upside depends on Rapport showing it can enroll and run the two planned RAP-219 Phase 3 studies at scale while converting the Tenacia Greater China deal into tangible economics beyond the disclosed $20 million upfront and potential milestone structure; this is meaningful but still early and execution-heavy [#10-K-2026-03-10].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology